NOP53 and ovarian carcinoma: Expression changes of HMGB1, HMGB2, MIEN1 and NOP53 genes have been evaluated in response to drugs usually employed in ovarian cancer treatments: bevacizumab, olaparib, paclitaxel or carboplatin.